News und Abstract des Monats

This podcast is designed for experts in the field of vasculitis, as well as anyone interested in learning more about these complex autoimmune diseases. Each episode features a new expert guest, offering insights on diagnosing, managing, and treating vasculitis in its many forms, along with the latest scientific updates and personal reflections to enrich your clinical practice.

What can you expect?

- Updates on current research and advances in vasculitis

- Discussions on the latest clinical guidelines and practical applications

-Personal perspectives from leading experts

The episodes are to be found on the EUVAS website Podcasts – EUVAS

VASAS nimmt ab sofort Förderanträge entgegen. Nutzen Sie diese Chance, die Vasculitis-Forschung zu unterstützen und reichen Sie Ihren Antrag bis zum 31. Oktober 2025 ein.

Alle Informationen zu Teilnahmeberechtigung, Förderumfang und Bewerbungsverfahren finden Sie auf unserer Detailseite.

This randomized, double-blind, placebo-controlled, parallel-group trial (BACHELOR) evaluated the efficacy and safety of baricitinib, a Janus kinase 1/2 inhibitor, in patients with recent-onset polymyalgia rheumatica (PMR) without initial use of oral glucocorticoids.

Giant Cell Arteritis (GCA) is a serious condition that causes inflammation of the blood vessels, primarily affecting older adults. If left untreated, it can lead to permanent vision loss or stroke. Doctors often rely on two blood tests - ESR (Erythrocyte Sedimentation Rate) and CRP (C-Reactive Protein) - to help diagnose GCA, as these are typically elevated in active disease. However, some patients (about 4-15%) have only ESR or CRP elevated, and 1% have both normal despite having active vasculitis [2].

Ziel ist es, über eine kurze, (anonyme) Umfrage andere EGPA-Patienten zu finden und mehr über deren Bedürfnisse und Interessen zu erfahren - insbesondere im Hinblick auf die mögliche Gründung einer EGPA-Patientengruppe in der Schweiz.

The management of Takayasu arteritis (TAK) remains challenging due to its relapsing nature, often requiring long-term therapy over years. Given the risks of refractory disease and glucocorticoid-related (GC) toxicity, safe and sustained GC-sparing strategies are essential.

On April 8, 2025, the European Medicines Agency (EMA) approved upadacitinip for the treatment of RCA (LINK: AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis - Apr 8, 2025), this extension of indication is based on the data from the SELECT-GCA study now also presented in the full publication.

Relaspes are frequent in ANCA-associated vasculitis. Strategies to individualize treatment to prevent relapses while not putting patients at unnecessary risk for infections or adverse events of treatments is an unmet need.

Giant cell arteritis (GCA) requires urgent diagnosis and treatment because of the potential for vision loss. This manuscript describes a predictive tool (called the HAS-GCA score) to assess the post-test probability of GCA.

Kidney and lung involvement constitute key disease features and largely confer higher disease burden and mortality in patients with ANCA-associated vasculitis (AAV). Lung biopsy is only performed in a minority of cases and diagnosis of lung involvement relies on clinical and imaging findings.

The complement pathway is critically involved in many autoimmune diseases including vasculitides. In a multinational effort, Triaille and colleagues studied the clinical manifestations and in vivo activation of the type 1 interferon pathway in twelve patients with hereditary C1q deficiency (C1QDef).